Bordet, when working in Pasteur’S laboratory in Paris in 1896, observed that serum of animals immunized with bacteria (Vibrio cholerae), could agglutinate and lyse those bacteria in vitro (either in a test tube or on a slide). If, however, the serum was left at room temperature for one week, or briefly heated at 60 °C, the agglutinating activity remained unchanged but the ability to lyse bacteria was lost. The lytic activity could be restored by adding fresh serum from a non-immunized animal to the bacteria-heated serum mixture. On the basis of this experiment, Bordet assumed that lysis of bacteria required the presence of two factors; specific, agglutinating antibodies (discovered by Behring in 1889) and a non-specific component that was activated secondarily and was responsible for bacterial lysis and killing. Bordet called the latter component “alexin”. Soon after this discovery, particularly when further data were obtained by Ehrlich, the non-specific serum component was renamed “complement”.
KeywordsSystemic Lupus Erythematosus Polypeptide Chain Alternative Pathway Complement System Complement Component
Unable to display preview. Download preview PDF.
- Bashford, C. L., Alder, G. M., Menestrina, G., Micklem, K. J., Murphy, J. J. and Pasternak, C. A. (1986) Membrane damage by haemolytic viruses, toxins, complement and other cytotoxic agents: a common mechanism blocked by divalent cations. J. Biol. Chem. ,261, 9300–8.Google Scholar
- Becherer, J. D., Alsenz, J., Servis, C., Myones, B. L. and Lambris, J. D. (1989) Cell surface proteins reacting with activated complement components. Complement Inflamm. ,6, 152–65.Google Scholar
- Bhakdi, S. and Tranum-Jensen, J. (1984) Mechanism of complement cytoplysis and the concept of channel-forming proteins. Phil. Trans. R. Soc. Lond. ,B306, 311–24.Google Scholar
- Di Scipio, R.G. and Hugh, T. E. (1985) The architecture of complement component C9 and poly(C9). J. Biol. Chem. ,260, 14802–9.Google Scholar
- Di Scipio, R. G. and Hugli, T. E. (1989) The molecular architecture of human complement component C6. J. Biol. Chem. ,264, 16197–206.Google Scholar
- Joiner, K. A., Schmetz, M. A., Sanders, M. E., Murray, T. G., Hammer, C. H., Dourmashkin, R. and Frank, M. M. (1985) Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9. Proc. Natl. Acad. Sci. USA ,82, 4802–12. Kay, P. H. and Papadimitriou, J. M. (1990) What’s new in the role of complement in diseases? Pathol. Res. Pract. ,186, 410–4.CrossRefGoogle Scholar
- Morgan, B. P. (1989) Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem. J. ,264, 1–14.Google Scholar
- Reid, K. B. M. and Porter, R. R. (1976) Subunit composition and structure of subcomponent C1q of the first component of human complement. Biochem. J. ,155, 19–23.Google Scholar
- Staršia, Z. (1987) Clinical importance of complement. Prague, Avicenum, pp. 53–95 (in Slovak).Google Scholar